Professor of Medicine, University Tex SW Dallas
Nephrology
Dr. Robert D. Toto, MD
|
|
Give Review
Robert Toto practices Nephrology. He went to University of Texas Southwestern Medical School. He has 3 awards "America's Top Doctors", "CMS Meaningful Use Stage 1 Certification" and "Super Doctor". Dr. Robert D. Toto is also published. He has 49 publications published. The lastest publication: "Differences in Whole Blood Platelet Aggregation at Baseline and in Response to Aspirin and Aspirin Plus Clopidogrel in Patients With Versus Without Chronic Kidney Dise...' He is registered with Medicare and accepts Medicare payments.
Publications
- Differences in Whole Blood Platelet Aggregation at Baseline and in Response to Aspirin and Aspirin Plus Clopidogrel in Patients With Versus Without Chronic Kidney Dise...
- The effects of weight change on glomerular filtration rate.
- Managing Hypertension in Patients With CKD: A Marathon, Not a SPRINT.
- Mineralocorticoid receptor activation and mineralocorticoid receptor antagonist treatment in cardiac and renal Diseases.
- Effect of Low Versus High Dialysate Sodium Concentration on Blood Pressure and Endothelial-Derived Vasoregulators During Hemodialysis: A Randomized Crossover Study.
- Potassium handling With dual Renin-Angiotensin system inhibition in diabetic nephropathy.
- Bardoxolone methyl in type 2 diabetes and stage 4 chronic Kidney disease.
- The pathogenesis and management of hypertension in diabetic Kidney disease.
- A trial of 2 strategies to reduce nocturnal blood pressure in blacks with chronic Kidney disease.
- Current Update in the Management of Diabetic Nephropathy.
- Rationale and design of the Chronic Kidney Disease Antidepressant Sertraline Trial (CAST).
- A method for isolation and identification of urinary biomarkers in patients With diabetic nephropathy.
- Intradialytic hypertension and its association With endothelial cell dysfunction.
- Differential outcomes between dialysis modalities: purely a reflection of selection bias?
- Association between major depressive episodes in patients with chronic Kidney disease and initiation of dialysis, hospitalization, or death.
- Addition of angiotensin receptor blockade or Mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy.
- Is choice of antiHypertensive agent important in improving cardiovascular outcomes in high-risk Hypertensive patients?
- Association of blood pressure increases during hemodialysis With 2-year mortality in incident hemodialysis patients: a secondary analysis of the Dialysis Morbidity and...
- Decreased pulse pressure during hemodialysis is associated With improved 6-month outcomes.
- Validation of depression screening scales in patients With CKD.
- Prevalence of major depressive episode in CKD.
- Anemia, diabetes, and chronic Kidney disease.
- Disparate estimates of hypertension control from ambulatory and clinic blood pressure measurements in hypertensive Kidney disease.
- Effects of Calcium channel blockers on proteinuria in patients with diabetic nephropathy.
- Improving outcomes in hemodialysis patients: the need for well-designed clinical trials.
- Resistant Hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Counci...
- Reducing cardiovascular events in high-risk patients: the challenge of managing hypertension in patients With diabetic renal disease.
- Statins and cardiovascular risk reduction in patients with chronic Kidney disease and end-stage renal failure.
- Effect of ruboxistaurin on urinary transforming growth factor-beta in patients with diabetic nephropathy and type 2 Diabetes.
- Epithelial sodium channel inhibition in cardiovascular Disease. A potential role for amiloride.
- Lessons from the African-American Study of Kidney Disease and Hypertension: an update.
- Hemodialysis timing, survival, and cardiovascular outcomes in the Hemodialysis (HEMO) Study.
- Pressure, waves, and Kidney outcomes in Kidney transplant donors and recipients.
- The effect of ruboxistaurin on nephropathy in type 2 Diabetes.
- Treatment of hypertension in chronic Kidney disease.
- Proteinuria reduction: mandatory consideration or option when selecting an antiHypertensive agent?
- Intradialytic blood volume monitoring in ambulatory hemodialysis patients: a randomized trial.
- Management of hypertensive chronic Kidney disease: role of calcium channel blockers.
- Rationale--Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT): evolving the management of cardiovascular risk in patients with chronic Kidney disease.
- Lessons learned from recent clinical trials in hypertensive diabetics: what's good for the Kidney is good for the heart and brain.
- Microalbuminuria: definition, detection, and clinical significance.
- Proteinuria and Hypertensive nephrosclerosis in African Americans.
- Anemia and end-stage renal disease in patients with type 2 Diabetes and nephropathy.
- ACE inhibitors and target organ protection. An expanded role for these antiHypertensive agents?
- Anemia of Chronic disease: past, present, and future.
- Outcome studies in diabetic Nephropathy.
- Appropriate drug therapy for improving outcomes in diabetic Nephropathy.
- Sympathetic nervous system function in Renal hypertension.
Schools
University Of Illinois College Of Medicine Chicago
Baylor College Of Med
University Of Mi Hosps and Health Ctrs
University Tx Southwestern Med School
Procedures Preformed
- Hemodialysis
Conditions Treated
- Acidosis
- Acute Kidney Failure
- Calcium Metabolism Disorders
- Chronic Glomerulonephritis
- View All
Doctors Specialties
- Critical Care Medicine
- Nephrology
Accepted Insurances
Awards
- America's Top Doctors
- CMS Meaningful Use Stage 1 Certification
- Super Doctor
Education
-
University of Texas Southwestern Medical School -
Baylor College of Medicine -
University of Michigan Hospitals and Health Centers -
University of Illinois College of Medicine
Hospital
-
University of Texas Southwestern Medical Center -
Parkland Health & Hospital System
Drug Facts
| NPI NUMBER | 1245209725 | |
| NPPES Provider LastName | TOTO | |
| NPPES Provider FirstName | ROBERT | |
| NPPES Provider ZIPCode | 753907208 | |
| NPPES Provider State | TX | |
| Specialty Description | Internal Medicine | |
| Total Claim Count | 463.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1245209725 |
| Last Name Of The Provider | TOTO |
| First Name Of The Provider | ROBERT |
| View All |
Similar Doctors
|
|
Dr. Henry W. Ntende, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Anthony Ortegon, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Kosunarty Fa, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Steven R. Hays, MD |
|
|
Dr. Biff F. Palmer, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
Dr. Sandra Lauriat, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Alfredo R. Arauco Brown, MD |
|
|
Dr. Amir S. Alizadeh Naderi, MD |
|
|
Dr. Renuka Chowdhury, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Stephen Lee, MD |
|
|
Dr. Matthew J. Leveno, MD |
|
|
Dr. Tapan J. Patel, MD
This Doctor is OpenDoctor Recommended.
|